[HTML][HTML] Prophylactic HPV vaccines and prevention of cervical intraepithelial neoplasia
ER Heitmann, DM Harper - Current Obstetrics and Gynecology Reports, 2012 - Springer
Cervical cancer kills women of all ages. The irrefutable link to oncogenic human
papillomavirus (HPV), a sexually transmitted infection, forever changed society's attitude …
papillomavirus (HPV), a sexually transmitted infection, forever changed society's attitude …
Benefits, cost requirements and cost-effectiveness of the HPV16, 18 vaccine for cervical cancer prevention in developing countries: policy implications
Approximately 70% of cases of cervical cancer worldwide are caused by genotypes 16 and
18 of human papillomavirus (HPV), which is sexually transmitted. With the availability of an …
18 of human papillomavirus (HPV), which is sexually transmitted. With the availability of an …
Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis
With the recent advent of cervical cancer vaccines, many questions relating to the best
overall prevention methods for cervical disease are beginning to arise. A Markov model was …
overall prevention methods for cervical disease are beginning to arise. A Markov model was …
[HTML][HTML] Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis
Background Since 2006, many countries have implemented publicly funded human
papillomavirus (HPV) immunisation programmes. However, global estimates of the extent …
papillomavirus (HPV) immunisation programmes. However, global estimates of the extent …
[HTML][HTML] Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study
Background Funding for human papillomavirus (HPV) vaccination in Japan began in 2010
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …
[HTML][HTML] Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore
SK Tay, BW Lee, WY Sohn, IH Lee… - Singapore medical …, 2018 - ncbi.nlm.nih.gov
METHODS A lifetime Markov cohort model was used to evaluate the cost-effectiveness of
introducing the AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) to the current …
introducing the AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) to the current …
Age of acquiring causal human papillomavirus (HPV) infections: leveraging simulation models to explore the natural history of HPV-induced cervical cancer
EA Burger, JJ Kim, S Sy… - Clinical Infectious Diseases, 2017 - academic.oup.com
Background Although new human papillomavirus (HPV) infections can occur at all ages, the
age at which women acquire their “causal” HPV infection that develops into cervical cancer …
age at which women acquire their “causal” HPV infection that develops into cervical cancer …
HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing country
R Murillo, M Molano, G Martínez… - … in Obstetrics and …, 2009 - Wiley Online Library
Human Papillomavirus (HPV) vaccines have been considered potentially cost‐effective for
the reduction of cervical cancer burden in developing countries; their effectiveness in a …
the reduction of cervical cancer burden in developing countries; their effectiveness in a …
Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines
Background: The human papillomavirus (HPV) is a common sexually transmitted infection
and a primary cause of cervical cancer. The Government of Canada has set a target of …
and a primary cause of cervical cancer. The Government of Canada has set a target of …
[HTML][HTML] Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China)
B Serrano, L Alemany, PA de Ruiz, S Tous, MA Lima… - Cancer …, 2014 - Elsevier
Background We estimated the potential impact of an investigational 9-valent human
papillomavirus (HPV) vaccine (HPVs 6/11/16/18/31/33/45/52/58) in HPV-related cervical …
papillomavirus (HPV) vaccine (HPVs 6/11/16/18/31/33/45/52/58) in HPV-related cervical …